Abiopharma

Innate Pharma Releases Its 2026 Financial Calendar

Indivior Notification

Natera - Phase III PALLAS Study Shows Signatera™MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate RiskHR+/HER2‑ Breast Cancer

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

Takeda’s FY2025 Interim Business Report

Mirum Pharma - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ResMed Inc. Daily Stock Update

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm